Research programme: targeted cancer therapeutics - Intrexon/ZIOPHARM

Drug Profile

Research programme: targeted cancer therapeutics - Intrexon/ZIOPHARM

Alternative Names: ACT-based immunotherapy - Intrexon/ZIOPHARM; Adoptive cell transfer-based immunotherapy - Intrexon/ZIOPHARM; Anti-CD3-anti-EGFR CLM - Intrexon/ZIOPHARM; CAR-T cell therapeutics - Intrexon/ZIOPHARM/Merck Serono; Cell linking moieties - Intrexon/ZIOPHARM; Cetux-CAR T cells - Intrexon/ZIOPHARM; CLM expressing allogeneic cell therapeutics - Intrexon/ZIOPHARM; ERC-RTS-CLM; Natural killer cells - Ziopharm; Nimo-CAR T cells - Intrexon/ZIOPHARM; NK cells - Ziopharm; Non-viral adoptive cellular cancer immunotherapies - Intrexon/ZIOPHARM; pRTS-IFNα; RTS-IFNα

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer Intrexon Corporation; Merck Serono; University of Texas M. D. Anderson Cancer Center; ZIOPHARM Oncology
  • Class Bispecific antibodies; CAR-T cell therapies; Cell therapies; Gene therapies; Natural killer cell therapies
  • Mechanism of Action Apoptosis stimulants; Gene expression modulators; Gene transference; Immunostimulants; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer; Cancer
  • Research Non-small cell lung cancer

Most Recent Events

  • 06 Nov 2017 Zymogen Oncology plans to file an IND application with the US FDA once ongoing validation of the manufacturing process at NCI is complete in the first quarter of 2018
  • 01 May 2017 Ziopharm plans a phase I trial for Solid tumours in the second half of 2018
  • 16 Feb 2017 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top